BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26572750)

  • 1. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.
    Lo L; Patel D; Townsend AR; Price TJ
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1907-24. PubMed ID: 26572750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
    Peeters M; Karthaus M; Rivera F; Terwey JH; Douillard JY
    Drugs; 2015 May; 75(7):731-48. PubMed ID: 25895463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic colorectal cancer- third line therapy and beyond.
    Foo T; Roy A; Karapetis C; Townsend A; Price T
    Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
    Sickmier EA; Kurzeja RJ; Michelsen K; Vazir M; Yang E; Tasker AS
    PLoS One; 2016; 11(9):e0163366. PubMed ID: 27658254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary and acquired resistance to biologic therapies in gastrointestinal cancers.
    Lubner SJ; Uboha NV; Deming DA
    J Gastrointest Oncol; 2017 Jun; 8(3):499-512. PubMed ID: 28736637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents.
    El Zouhairi M; Charabaty A; Pishvaian MJ
    Gastrointest Cancer Res; 2011 Jan; 4(1):15-21. PubMed ID: 21464866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of metastatic colorectal cancer with panitumumab.
    López-Gómez M; Merino M; Casado E
    Clin Med Insights Oncol; 2012; 6():125-35. PubMed ID: 22408376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer.
    Yazdi MH; Faramarzi MA; Nikfar S; Abdollahi M
    Avicenna J Med Biotechnol; 2015; 7(4):134-44. PubMed ID: 26605007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.
    Wang J; Hechmati G; Dong J; Maglinte GA; Barber B; Douillard JY
    Curr Med Res Opin; 2016; 32(3):459-65. PubMed ID: 26613286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
    Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
    Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma.
    Cheng L; Xia Z; Bian X; Li G; Hu J; Cao Y; Wang Q; Qian X
    Onco Targets Ther; 2015; 8():3185-92. PubMed ID: 26586952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
    Hubbard JM; Kim G; Borad MJ; Johnson E; Qin R; Lensing J; Puttabasavaiah S; Wright J; Erlichman C; Grothey A
    Invest New Drugs; 2016 Feb; 34(1):96-103. PubMed ID: 26581401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.
    Sato Y; Matsusaka S; Suenaga M; Shinozaki E; Mizunuma N
    Onco Targets Ther; 2015; 8():3329-36. PubMed ID: 26648737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avatars Identify Genetic Sources of Drug Response.
    Cancer Discov; 2016 Jan; 6(1):OF9. PubMed ID: 26573662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
    Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
    PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
    Russo M; Siravegna G; Blaszkowsky LS; Corti G; Crisafulli G; Ahronian LG; Mussolin B; Kwak EL; Buscarino M; Lazzari L; Valtorta E; Truini M; Jessop NA; Robinson HE; Hong TS; Mino-Kenudson M; Di Nicolantonio F; Thabet A; Sartore-Bianchi A; Siena S; Iafrate AJ; Bardelli A; Corcoran RB
    Cancer Discov; 2016 Feb; 6(2):147-153. PubMed ID: 26644315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance strategy in metastatic colorectal cancer: A systematic review.
    Esin E; Yalcin S
    Cancer Treat Rev; 2016 Jan; 42():82-90. PubMed ID: 26608114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
    Li J; Srivastava RM; Ettyreddy A; Ferris RL
    J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.